Role of the δ-Opioid Receptor in 2 Murine Models of Colitis.
暂无分享,去创建一个
[1] B. Vrooman,et al. Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization , 2018, Medical sciences.
[2] L. Småbrekke,et al. The Effect of Low-Dose Naltrexone on Medication in Inflammatory Bowel Disease: A Quasi Experimental Before-and-After Prescription Database Study , 2018, Journal of Crohn's & colitis.
[3] A. Dalgleish,et al. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors , 2017, Front. Immunol..
[4] Mahmoud M. Kamel,et al. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats , 2016, Neuropeptides.
[5] G. Kaplan,et al. The global burden of IBD: from 2015 to 2025 , 2015, Nature Reviews Gastroenterology &Hepatology.
[6] Y. Zhang,et al. Pharmacological characterization of the opioid inactive isomers (+)‐naltrexone and (+)‐naloxone as antagonists of toll‐like receptor 4 , 2015, British journal of pharmacology.
[7] L. Watkins,et al. In vivo veritas: (+)-Naltrexone's actions define translational importance: A letter in response to Skolnick et al. 'Translational potential of naloxone and naltrexone as TLR4 antagonists'. , 2014, Trends in pharmacological sciences.
[8] Nirmal Singh,et al. A Review on Chemical-Induced Inflammatory Bowel Disease Models in Rodents , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.
[9] J. Younger,et al. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain , 2014, Clinical Rheumatology.
[10] M. Platt,et al. Crohn's disease: a review of treatment options and current research. , 2013, Cellular immunology.
[11] J. Whistler,et al. Pharmacological traits of delta opioid receptors: pitfalls or opportunities? , 2013, Psychopharmacology.
[12] S. Devkota,et al. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases , 2013, Journal of Gastroenterology.
[13] L. Carbone. Pain management standards in the eighth edition of the Guide for the Care and Use of Laboratory Animals. , 2012, Journal of the American Association for Laboratory Animal Science : JAALAS.
[14] I. Zagon,et al. Targeting opioid signaling in Crohn’s disease: new therapeutic pathways , 2011, Expert review of gastroenterology & hepatology.
[15] I. Zagon,et al. Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model , 2011, Experimental biology and medicine.
[16] Christopher O. McGovern,et al. Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled Trial , 2011, Digestive Diseases and Sciences.
[17] C. Hofmann,et al. 4SC‐101, a novel immunosuppressive drug, inhibits IL‐17 and attenuates colitis in two murine models of inflammatory bowel disease† , 2010, Inflammatory bowel diseases.
[18] P. Kosmidis,et al. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. , 2009, Anticancer research.
[19] Gang Lu,et al. A γ-Tocopherol–Rich Mixture of Tocopherols Inhibits Colon Inflammation and Carcinogenesis in Azoxymethane and Dextran Sulfate Sodium–Treated Mice , 2009, Cancer Prevention Research.
[20] M. Fischer,et al. Toll‐like Receptors in Autoimmunity , 2008, Annals of the New York Academy of Sciences.
[21] Christopher O. McGovern,et al. The Opioid Antagonist Naltrexone Improves Murine Inflammatory Bowel Disease , 2008, Journal of immunotoxicology.
[22] Moshe Rogosnitzky,et al. Low-Dose Naltrexone Therapy Improves Active Crohn's Disease , 2007, The American Journal of Gastroenterology.
[23] Stefan Wirtz,et al. Chemically induced mouse models of intestinal inflammation , 2007, Nature Protocols.
[24] M. Puig,et al. Antiexudative Effects of Opioids and Expression of κ- and δ- Opioid Receptors during Intestinal Inflammation in Mice: Involvement of Nitric Oxide , 2006, Journal of Pharmacology and Experimental Therapeutics.
[25] J. R. Palacio,et al. The Expression of δ- and κ-Opioid Receptor Is Enhanced during Intestinal Inflammation in Mice , 2003, Journal of Pharmacology and Experimental Therapeutics.
[26] G. Bouma,et al. The immunological and genetic basis of inflammatory bowel disease , 2003, Nature Reviews Immunology.
[27] Juan Zhang,et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. , 2002, Gastroenterology.
[28] I. Fuss,et al. Induction of TNBS colitis in mice. , 2002, Current protocols in immunology.
[29] H. Ogata,et al. Animal models of inflammatory bowel disease , 2002, Journal of Gastroenterology.
[30] F. Alameda,et al. Inflammation enhances mu-opioid receptor transcription and expression in mice intestine. , 2001, Molecular pharmacology.
[31] J. Wallace,et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. , 1996, The Journal of clinical investigation.
[32] H. Cooper,et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin , 1993, Digestive Diseases and Sciences.
[33] J. Wallace,et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. , 1989, Gastroenterology.
[34] E. Ruitenberg,et al. The ‘Swiss roll’: a simple technique for histological studies of the rodent intestine , 1981, Laboratory animals.
[35] S. Spampinato,et al. Opioid Receptors , 2015, Methods in Molecular Biology.
[36] Anupama Koneru,et al. Endogenous Opioids: Their Physiological Role and Receptors , 2009 .
[37] L. Fitzpatrick,et al. In vitro and in vivo effects of gliotoxin, a fungal metabolite: efficacy against dextran sodium sulfate-induced colitis in rats. , 2000, Digestive diseases and sciences.
[38] T. Ohkusa,et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. , 1990, Gastroenterology.
[39] I. Leodolter. [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.